By a News Reporter-Staff News Editor at Cardiovascular Week -- Research findings on Heart Diseases and Conditions are discussed in a new report. According to news reporting from Groningen, Netherlands, by NewsRx journalists, research stated, "Many chronic heart failure (CHF) patients have low vitamin D (VitD) and high plasma renin activity (PRA), which are both associated with poor prognosis. Vitamin D may inhibit renin transcription and lower PRA."
The news correspondents obtained a quote from the research from the University of Groningen, "We investigated whether vitamin D3 (VitD3) supplementation lowers PRA in CHF patients. We conducted a single-center, open-label, blinded end point trial in 101 stable CHF patients with reduced left ventricular ejection fraction. Patients were randomized to 6 weeks of 2,000 IU oral VitD3 daily or control. At baseline, mean age was 64 +/- 10 years, 93% male, left ventricular ejection fraction 35% +/- 8%, and 56% had VitD deficiency. The geometric mean (95% CI) of 25-hydroxyvitamin D3 increased from 48 nmol/L (43-54) at baseline to 80 nmol/L (75-87) after 6 weeks in the VitD3 treatment group and decreased from 47 nmol/L (42-53) to 44 nmol/L (39-49) in the control group (P < .001). The primary outcome PRA decreased from 6.5 ng/mL per hour (3.8-11.2) to 5.2 ng/mL per hour (2.9-9.5) in the VitD3 treatment group and increased from 4.9 ng/mL per hour (2.9-8.5) to 7.3 ng/mL per hour (4.5-11.8) in the control group (P = .002). This was paralleled by a larger decrease in plasma renin concentration in the VitD3 treatment group compared to control (P = .020). No significant changes were observed in secondary outcome parameters, including N-terminal pro-B-type natriuretic peptide natriuretic peptide and fibrosis markers. Most CHF patients had VitD deficiency and high PRA levels."
According to the news reporters, the research concluded: "Six weeks of supplementation with 2,000 IU VitD3 increased 25-hydroxyvitamin D3 levels and decreased PRA and plasma renin concentration."
For more information on this research see: Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: An open-label, blinded end point, randomized prospective trial (VitD-CHF trial). American Heart Journal, 2013;166(2):357-364,250-251. American Heart Journal can be contacted at: Mosby-Elsevier, 360 Park Avenue South, New York, NY 10010-1710, USA. (Elsevier - www.elsevier.com; American Heart Journal - www.elsevier.com/wps/product/cws_home/623272)
Our news journalists report that additional information may be obtained by contacting N.F. Schroten, University of Groningen, Groningen University Medical Center, Trial Coordinat Center, Groningen, Netherlands. Additional authors for this research include W.P.T. Ruifrok, L. Kleijn, M.M. Dokter, H.H. Sillje, H.J.L. Heerspink, S.J.L. Bakker, I.P. Kema, W.H. van Gilst, D.J. van Veldhuisen, H.L. Hillege and R.A. de Boer (see also Heart Diseases and Conditions).
Keywords for this news article include: Renin, Europe, Groningen, Treatment, Cardiology, Netherlands, Heart Attack, Peptide Hydrolases, Chronic Heart Failure, Enzymes and Coenzymes, Proprotein Convertases, Cardiovascular Diseases, Aspartic Acid Endopeptidases, Heart Diseases and Conditions
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .
Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.